2025-2030年全球神经退化性疾病新治疗方法市场

Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030

出版日期: 2025年08月19日 | 出版商:

Frost & Sullivan | 英文 39 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

推动神经系统疾病未来的创新策略

本报告对包括阿兹海默症和帕金森氏症在内的神经退化性疾病治疗的现状和未来进行了全面检验，强调了关键的成长动力（如精准医疗、诊断的人工智慧范式以及老龄化的变革大趋势）及其面临的障碍（如竞争性质和地缘政治动盪）。

本报告探讨了新兴治疗方法，包括生物製药（单株抗体、核酸疗法）、小分子药物（淀粉样变性抑制剂、NMDA 拮抗剂）以及替代疗法（临床营养保健品、微生物组）。报告也检验了融合与颠覆等重要策略，以及来自知名学术机构和产业相关人员的关键新药和新设备的研发管线回顾。报告还重点分析了疾病修正治疗、免疫疗法药物和精准医疗领域的高成长机会，以及融资趋势和与策略伙伴的合作。

该研究整合了技术、临床和市场趋势，为相关人员提供可行的建议，并强调新兴神经退化治疗领域数兆美元的高成长机会。

神经退化性疾病的事实与挑战
了解与老龄化相关的最普遍、影响最深远的脑部疾病
阿兹海默症和帕金森氏症是主要的神经退化性疾病
神经退化性疾病的新型生物製药治疗方法
机转与临床应用：核酸治疗
单株抗体的作用机转及临床应用
微生物治疗的机转及临床应用
神经退化性疾病的新型小分子治疗方法
淀粉样变性抑制剂的作用机转及临床应用
NMDA受体拮抗剂的作用机转及临床应用
胆碱酯酶抑制剂的作用机转及临床应用
神经退化性疾病的替代疗法
膳食补充剂的作用机转及临床应用
机制与临床应用：阿育吠陀与传统医学

创新前景：阿兹海默症和帕金森氏症临床管线概述

阿兹海默症临床管线概述
临床研发管线创新者简介
帕金森氏症临床管线概述
临床研发管线创新者简介

资金筹措、伙伴关係与收购

资金筹措分析
重要伙伴关係与收购

前景

创新生物递送系统的前景
特异性单株抗体的前景
基因治疗与基因工程的观点

神经退化性疾病领域的成长机会

成长机会1：精准医疗与个人化治疗的进步
增长机会二：疾病修正治疗的突破
成长机会3：免疫治疗方法的进展

后续步骤Next steps

成长机会的益处和影响
后续步骤Next steps
免责声明

简介目录

Product Code: DB2D

Innovative Strategies Driving the Future of Neuro Diseases

This report is a thorough examination of the current and future face of therapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's. It articulates important growth drivers (e.g., precision medicine, AI paradigm for diagnostics, and the transformational megatrends of aging populations) and barriers they will face (e.g., the nature of competition and geopolitical upheaval).

The report will examine emerging therapeutic modalities including biologics (monoclonal antibodies and nucleic acid therapies), small molecules (amyloidogenesis inhibitors and NMDA antagonists), and alternative therapies (clinical nutraceuticals and microbiome). It also examines essential strategies such as convergence and disruption, as well as pipeline reviews of major emerging drugs and devices from prominent academic and industry participants. It pinpoints high-growth opportunities, such as disease-modifying therapies, immunotherapy drug products, and precision medicine along with funding trends and collaborations with strategic partners.

The study integrates technological, clinical, and market trends to provide actionable recommendations to stakeholders and emphasize the high-growth, multitrillion-dollar opportunities in the emerging neurodegenerative therapeutics space.

Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8
The Impact of the Top 3 Strategic Imperatives on Emerging Therapeutics for Neurodegenerative Diseases
Growth Opportunities Fuel the Growth Pipeline Engine
Research Methodology

Growth Opportunity Analysis

Scope of Analysis
Segmentation

Growth Generator

Growth Drivers
Growth Restraints

Emerging Therapies to Address Neurodegenerative Diseases

Neurodegenerative Diseases: Facts and Challenges
Understanding the Most Prevalent and Impactful Disorders of the Aging Brain
Alzheimer's and Parkinson's Diseases Are the Leading Neurodegenerative Disorders
Neurodegenerative Diseases: Emerging Therapies Under Biologics
Mechanism and Clinical Applications: Nucleic Acid Therapies
Mechanism and Clinical Applications: Monoclonal Antibodies
Mechanism and Clinical Applications: Microbiome-Based Therapies
Neurodegenerative Diseases: Emerging Therapies Under Small Molecules
Mechanism and Clinical Applications: Amyloidogenesis Inhibitors
Mechanism and Clinical Applications: NMDA Receptor Antagonist
Mechanism and Clinical Applications: Cholinesterase Inhibitors
Neurodegenerative Diseases: Alternative Therapies
Mechanism and Clinical Applications: Nutraceuticals
Mechanism and Clinical Applications: Ayurvedic and Traditional Practices

Innovation Landscape: Clinical Pipeline Overview For Alzheimer's and Parkinson's Disease

Clinical Pipeline Overview for Alzheimer's
Clinical Pipeline Innovator Profiles
Clinical Pipeline Overview for Parkinson's
Clinical Pipeline Innovator Profiles

Funding, Partnerships, and Acquisitions

Funding Analysis
Key Partnerships and Acquisitions

Outlook

Innovative Biologic Delivery Systems Outlook
Target-Specific Monoclonal Antibodies Outlook
Gene Therapy and Genetic Engineering Outlook

Growth Opportunity Universe For Neurodegenerative Diseases

Growth Opportunity 1: Advancements in Precision Medicine and Personalized Therapies
Growth Opportunity 2: Breakthroughs in Disease-Modifying Therapies
Growth Opportunity 3: Advancing Immunotherapeutic Approaches